Invention Publication
- Patent Title: CHLAMYDIA VACCINE BASED ON TARGETING MOMP VS4 ANTIGEN TO ANTIGEN PRESENTING CELLS
-
Application No.: US18269113Application Date: 2021-12-22
-
Publication No.: US20240131138A1Publication Date: 2024-04-25
- Inventor: Yves LEVY , Sylvain CARDINAUD , Mireille CENTLIVRE , Lydie DIEUDONNE , Sandra ZURAWSKI , Gérard ZURAWSKI
- Applicant: Institut National de la Santé et de la Recherche Médicale (INSERM) , Assistance Publique - Hopitaux de Paris , Baylor Research Institute , Universite Paris Est Creteil Val De Marne
- Applicant Address: FR TX Paris
- Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM),Assistance Publique - Hopitaux de Paris (APHP),Baylor Research Institute,Universite Paris Est Creteil Val De Marne
- Current Assignee: Institut National de la Santé et de la Recherche Médicale (INSERM),Assistance Publique - Hopitaux de Paris (APHP),Baylor Research Institute,Universite Paris Est Creteil Val De Marne
- Current Assignee Address: FR Paris; FR Paris; US TX Dallas; FR Creteil
- Priority: EP 306668.3 2020.12.23
- International Application: PCT/EP2021/087211 2021.12.22
- Date entered country: 2023-06-22
- Main IPC: A61K39/118
- IPC: A61K39/118 ; A61P31/04 ; C07K14/295 ; C07K16/28
Abstract:
Chlamydiae are intracellular bacterial pathogens responsible for a variety of infections. The inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain and/or light chain is conjugated to the MOMP VS4 domain of Chlamydia trachomatis for its use as vaccine.
Information query
